Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423389 | 0.99 | DPP7 (0.41) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL30446058 | 0.92 | MEN1 (0.41) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL29475359 | 0.92 | DPP7 (0.39) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL29746425 | 0.91 | DPP7 (0.43) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL30446089 | 0.91 | CALCRL (0.42) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL29876337 | 0.89 | REN (0.42) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL29641658 | 0.89 | CALCRL (0.45) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL29530970 | 0.87 | DPP7 (0.42) | DPP7CTSCMEN1KMT2ACYP3A4 | |
| SCHEMBL31688177 | 0.87 | PDCD1LG2 (0.45) | DPP7CTSCMEN1KMT2AREN | |
| SCHEMBL31023074 | 0.86 | DPP7 (0.43) | DPP7CTSCMEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145578-A1 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-05-08 | — | — | US | disclosed |
| WO-2023158866-A2 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145578-A1 | SMALL MOLECULES TARGETTING EIF3E TO INHIBIT TUMOR GROWTH PROGRESSION, AND METASTASIS | EIF2B3, EIF6, EIF2A | DPP7 4646/4885CTSC 4771/4885MEN1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.